Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).
Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase III study on midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 194).
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).
Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).
